Taxotere and Permanent Hair Loss Lawsuit
We are currently investigating a potential connection between the chemotherapy drug Taxotere and permanent, irreversible hair loss (alopecia), as well indications that the risk was known to the manufacturer but was withheld from patients and physicians.
What Is Taxotere?
Taxotere is made by Sanofi-Aventis and is the brand name of the chemotherapy drug docetaxel. Taxotere and its competitor Taxol (paclitaxel) are part of a class of drugs known as taxanes. Taxotere is used either alone or in combination therapy to treat various forms of cancer, including breast cancer.
Marketing Of Taxotere And FDA Warning Letter
Initially approved by the FDA in May 1996. It was promoted by Sanofi-Aventis as having superior efficacy over Taxol. In 2009, however, the FDA issued a warning letter to Sanofi-Aventis describing certain marketing material as false or misleading due to its presentation of unsubstantiated superiority claims and overstatement of the efficacy of Taxotere. The FDA stated that Sanofi-Aventis made claims that “misleadingly suggest that Taxotere is superior to paclitaxel in the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy and overstate the efficacy of Taxotere.” The FDA went on to state that it was “unaware of substantial evidence to support these claims .”
Risk Of Permanent Hair Loss (Alopecia)
Hair loss is a common side effect of chemotherapy treatment, affecting scalp, pubic and underarm hair, along with eyebrows and eyelashes. This hair loss is usually temporary and reversible, however, with complete hair regrowth occurring within 3-6 months after the final treatment.
Unfortunately, reports have begun to emerge of women surviving breast cancer only to be faced with permanent, irreversible hair loss following treatment with Taxotere. Not only does the hair not begin to regrow as expected, but it is not responsive to the various hair loss treatments. Studies have shown that a permanent loss of hair negatively and dramatically affects the quality of life for these cancer survivors, no matter the clinical degree of loss.
Unwarned Risks-Taxotere Lawsuit
It is alleged that Sanofi–Aventis knew or should have known that their drug, Taxotere, caused permanent alopecia (hair loss) at a greater rate than its competitors. Studies throughout the years suggested the connection between permanent alopecia and Taxotere. Furthermore, in December 2015, the Taxotere label was changed to include post-marketing experience that “cases of permanent alopecia have been reported,” even though drug information in Europe and Canada had warned of the alopecia risks years before.
Contact Us Today If You Suffered Permanent Hair Loss after Taxotere Treatment
If you have experienced permanent hair loss following breast cancer chemotherapy treatment with Taxotere, contact us today. Zoll & Kranz, LLC continues this ongoing investigation and stands with Plaintiffs to seek change. It is our goal to ensure accountability and promote the safety of individuals everywhere. It is an injustice to mislead cancer patients and their physicians, denying them the chance to make an informed choice about chemotherapy treatment. If you would like to talk to our product liability and mass tort attorneys, please fill out our form below or call us toll-free at 888-841-9623.
Please fill out the form for a complimentary product liability case evaluation involving Taxotere.